Neurogene NGNE Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Neurogene insiders were all sales, totaling $1.13 million (41.58K shares).

• Neurogene's open-market sales in the past 12 months came from 4 insiders; no insider bought.
• The largest open-market sales of NGNE in the past 12 months were by Christine Mikail Cvijic (President and CFO), totaling $900,023 (30.6K shares), most recently on July 7, 2026.
• Away from the open market, NGNE insiders received 69.3K shares in stock awards and acquired 756 shares through option exercises and conversions over the last 12 months.
• According to Business Quant data, insiders at Neurogene reported 3.19Mn shares in total in their latest Form 4 filings, down 0.28% from 3.2Mn shares at the end of Q2 2026.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 53.84% (1.72Mn shares) of Neurogene's insider total, with the other 46.16% (1.47Mn shares) held directly.
• Per Business Quant, 5 insiders of NGNE hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Neurogene's three biggest insider holders are Samsara Biocapital GP, LLC (10% owner, 1.72Mn shares), Rachel McMinn (Chief Executive Officer, 1.35Mn shares) and Christine Mikail Cvijic (President and CFO, 84.04K shares), based on their latest Form 4 filings.
• The largest insider, Samsara Biocapital GP, LLC, holds 53.84% of NGNE's insider total.
• Institutional investors held 76.77% of Neurogene stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 14.14%; other investors, including the public, hold roughly 9.09%.
• Over the past 12 months, 10 insiders reported transactions in Neurogene stock in 20 Form 4 filings.
• This summary of Neurogene insider activity covers Form 4 filings through October 2, 2026.